Literature DB >> 3103301

Antineoplastic drug cytotoxicity in a human bladder cancer cell line: implications for intravesical chemotherapy.

C Erlichman, D Vidgen, A Wu.   

Abstract

The clonogenic survival of MGH-U1 human bladder carcinoma cells treated with melphalan, cisplatin, mitomycin-C, adriamycin, vincristine and 5-fluorouracil was measured to determine the relative contribution of drug concentration and duration of exposure to cytotoxicity and to measure the relative cytotoxic effects of these agents used in intravesical chemotherapy. The survival curves were plotted as a function of log (C X T) and were fitted using a linear least squares analysis. The survival was the same for any given C X T whether this was determined by varying concentration or by varying the duration of exposure in the cases of melphalan, cisplatin, adriamycin, mitomycin-C and 5-fluorouracil. However, duration of exposure was more important than was drug concentration in the case of vincristine cytotoxicity. By utilizing the slope of the log (survival fraction) as a function of log (C X T), the relative cytotoxicity of each agent was determined. Mitomycin C, melphalan, adriamycin and cisplatin had comparable activity in this cell line, whereas vincristine and 5-fluorouracil demonstrated much lower cytotoxicity. We conclude that: mitomycin-C, adriamycin and melphalan were the agents with the greatest cytotoxic efficacy; determination of survival as a function of C X T can be used to separate the relative importance of concentration and of duration of exposure. the cytotoxicity of 5/6 drugs studied was equal when the C X T was kept constant but concentration and exposure times were varied.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3103301     DOI: 10.1007/bf00256328

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  15 in total

1.  Two types of ribosome in mouse-hamster hybrid cells.

Authors:  C P Stanners; G L Eliceiri; H Green
Journal:  Nat New Biol       Date:  1971-03-10

2.  Cell cycles in two cell lines of human bladder carcinoma.

Authors:  T Kato; R J Irwin; G R Prout
Journal:  Tohoku J Exp Med       Date:  1977-02       Impact factor: 1.848

3.  Pharmacologic rationale for regional drug delivery.

Authors:  J M Collins
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

4.  The need for long-term follow-up studies after treatment of superficial bladder cancer (Tis/Ta/T1), especially after intravesical chemotherapy.

Authors:  S D Fossa
Journal:  Prog Clin Biol Res       Date:  1985

Review 5.  The biology and treatment of superficial bladder cancer.

Authors:  F M Torti; B L Lum
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

6.  Superficial bladder cancer: progression and recurrence.

Authors:  N M Heney; S Ahmed; M J Flanagan; W Frable; M P Corder; M D Hafermann; I R Hawkins
Journal:  J Urol       Date:  1983-12       Impact factor: 7.450

7.  Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism.

Authors:  E Cadman; R Heimer; L Davis
Journal:  Science       Date:  1979-09-14       Impact factor: 47.728

8.  Establishment and characterization of four human bladder tumor cell lines and sublines with different degrees of malignancy.

Authors:  C W Lin; J C Lin; G R Prout
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

9.  Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis-platinum versus cis-platinum plus hyaluronidase.

Authors:  Y Horn; A Eidelman; N Walach; M Waron; F Barak
Journal:  J Surg Oncol       Date:  1985-04       Impact factor: 3.454

10.  Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line.

Authors:  P J Hepburn; R T Oliver; P A Riley; B T Hill; J R Masters
Journal:  Urol Res       Date:  1985
View more
  2 in total

1.  A mathematical model for cisplatin cellular pharmacodynamics.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

2.  Cisplatin Pharmacodynamics Following Endobronchial Ultrasound-Guided Transbronchial Needle Injection into Lung Tumors.

Authors:  Vitor Mori; Gregory S Roy; Jason H T Bates; C Matthew Kinsey
Journal:  Sci Rep       Date:  2019-05-02       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.